DA
BMY icon

Dunvegan Associates’s Bristol-Myers Squibb BMY Stock Holding History

Dunvegan Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$50K Hold
732
– – 0.06% 96
2015
Q3 		$43K Hold
732
– – 0.05% 100
2015
Q2 		$49K Buy
+732
New +$48.2K 0.05% 95

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dunvegan Associates's BMY Position: Q4 2015 in Review

Dunvegan Associates held its Bristol-Myers Squibb (BMY) position steady in Q4 2015 at 732 shares worth $50K. The position accounts for 0.06% of the portfolio, ranked #96.

Dunvegan Associates first reported a position in BMY in Q2 2015 and has held it in 3 quarters since. 1,535 funds tracked by Wall St. Rank hold BMY as of Q4 2015.

  • Dunvegan Associates held 732 shares of Bristol-Myers Squibb worth $50K as of Q4 2015.
  • Dunvegan Associates left its Bristol-Myers Squibb share count unchanged in Q4 2015.
  • Bristol-Myers Squibb made up 0.06% of Dunvegan Associates's portfolio in Q4 2015, its #96 holding.
  • Dunvegan Associates first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 3 quarters since.
  • 1,535 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.